EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross‐sectional associations with early cognitive impairments

Jessie Fanglu Fu iD, Arun Garimella, Alex Lapointe, William W T Aye, Charles D Chen, Joseph H Lee, Sharon J Krinsky-McHale, Shahid Zaman, Ira T Lott, Christy Hom, Beau Ances, Elizabeth Head und 11 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Jessie Fanglu Fu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA. Hauptthemen laut MEDLINE: Down Syndrome, tau Proteins, Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIBIB NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Individuals with Down syndrome (DS) have elevated risks for Alzheimer's disease (AD) due to amyloid beta (Aβ) precursor protein overexpression, with nearly all developing AD pathology by age 40 at autopsy. This study examined spatial associations between Aβ and tau burden in DS and neurotypical aging. METHODS Data included 145 DS (25–67 years) and 191 neurotypical aging individuals (63–89 years). Regional Aβ and tau positron emission tomography outcomes were analyzed using multiset canonical correlation analysis to identify joint Aβ/tau spatial patterns, with regression models assessing associations with age and cognition. RESULTS For a given Aβ burden, cognitively stable DS individuals exhibited relatively higher tau burden than neurotypical aging, while DS mild cognitive impairment/AD individuals exhibited more widespread pathology. Joint Aβ/tau patterns were associated with episodic memory impairment in DS and, as the disease progresses, executive dysfunction. DISCUSSION DS exhibits overlapping and distinct AD‐related neuropathology features, emphasizing the importance of biomarkers for early detection and intervention. Highlights There are distinct amyloid beta (Aβ) and tau spatial patterns in Down syndrome (DS): For a given level of Aβ burden, individuals with DS exhibited greater and more widespread tau burden compared to neurotypical aging, even before a clinical diagnosis of dementia. Aβ‐associated tau burden was linked to episodic memory impairment in DS prior to dementia, with executive dysfunction emerging as the disease progressed, highlighting the sequential impact of pathology on cognition. The unique pattern of early striatal Aβ accumulation in DS supports its use as a potential biomarker for tracking disease progression and guiding clinical trial inclusion criteria for Alzheimer's disease interventions in DS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down Syndrometau ProteinsAmyloid beta-PeptidesAlzheimer DiseaseCognitive DysfunctionBrainHumansMaleFemaleMiddle AgedAgedPositron-Emission TomographyCross-Sectional StudiesAdultAged, 80 and overBiomarkers

Stichwörter der Autor:innen

Alzheimer's diseaseDown syndromeamyloidmemorymultivariate analysispreclinicaltau

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.
  • Departments of Neurology and Epidemiology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.
  • Department of Psychology, The New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA.
  • Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Department of Pediatrics, University of California, Irvine, California, USA.
  • Department of Psychiatry and Human Behavior, University of California, Irvine, California, USA.

ORCID-Profile: Jessie Fanglu Fu

Förderung

  • NIA NIH HHS
  • NIBIB NIH HHS
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering

Zitieren

APA

Fu, J. F., Garimella, A., Lapointe, A., Aye, W. W. T., Chen, C. D., Lee, J. H., Krinsky-McHale, S. J., Zaman, S., Lott, I. T., Hom, C., Ances, B., Head, E., Mapstone, M., Lai, F., Handen, B. L., Laymon, C. M., Hartley, S. L., Christian, B. T., Rentz, D. M., …, & Alzheimer Biomarkers Consortium–Down Syndrome (ABC‐DS) (2025). Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross‐sectional associations with early cognitive impairments. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70424

Vancouver

Fu JF, Garimella A, Lapointe A, Aye WWT, Chen CD, Lee JH, et al. Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross‐sectional associations with early cognitive impairments. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70424

BibTeX
@article{Fu2025,
  author = {Fu, Jessie Fanglu and Garimella, Arun and Lapointe, Alex and Aye, William W T and Chen, Charles D and Lee, Joseph H and Krinsky-McHale, Sharon J and Zaman, Shahid and Lott, Ira T and Hom, Christy and Ances, Beau and Head, Elizabeth and Mapstone, Mark and Lai, Florence and Handen, Benjamin L and Laymon, Charles M and Hartley, Sigan L and Christian, Bradley T and Rentz, Dorene M and Johnson, Keith A and Rosas, H Diana and Price, Julie C and Alzheimer Biomarkers Consortium–Down Syndrome (ABC‐DS), Alzheimer Biomarkers Consortium–Down Syndrome (ABC‐DS)},
  title = {Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross‐sectional associations with early cognitive impairments},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70424}
}
Kostenlos starten →